Similar articles

• The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.

  Phillips AN, Bansi-Matharu L, Cambiano V, Ehrenkranz P, Serenata C, Venter F, Pett S, Flexner C, Jahn A, Revill P, Garnett GP. Phillips AN, et al. Lancet Glob Health. 2021 May;9(5):e620-e627. doi: 10.1016/S2214-109X(21)00025-5. Epub 2021 Mar 23. Lancet Glob Health. 2021. PMID: 33770513 Free PMC article.
• Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.

  Lowenthal ED, Chapman J, Ohrenschall R, Calabrese K, Baltrusaitis K, Heckman B, Yin DE, Agwu AL, Harrington C, Van Solingen-Ristea RM, McCoig CC, Adeyeye A, Kneebone J, Chounta V, Smith-Anderson C, Camacho-Gonzalez A, D'Angelo J, Bearden A, Crauwels H, Huang J, Buisson S, Milligan R, Ward S, Bolton-Moore C, Gaur AH; IMPAACT 2017 Collaborators; IMPAACT 2017 Team. Lowenthal ED, et al. Lancet HIV. 2024 Apr;11(4):e222-e232. doi: 10.1016/S2352-3018(23)00301-6. Lancet HIV. 2024. PMID: 38538161 Free PMC article. Clinical Trial.
• Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.

  Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, Gutierrez F, Sloan L, Clair MS, Murray M, Ford SL, Mrus J, Patel P, Crauwels H, Griffith SK, Sutton KC, Dorey D, Smith KY, Williams PE, Spreen WR. Margolis DA, et al. Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24. Lancet. 2017. PMID: 28750935 Clinical Trial.
• Clinical pharmacology considerations and drug-drug interactions with long-acting cabotegravir and rilpivirine relevant to sub-Saharan Africa.

  Steulet A, Obura B, Waitt C, Laker E, Nicol MR, Cresswell FV. Steulet A, et al. Br J Clin Pharmacol. 2024 Sep;90(9):2079-2091. doi: 10.1111/bcp.16154. Epub 2024 Jun 25. Br J Clin Pharmacol. 2024. PMID: 38923554 Review.
• Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV.

  Taramasso L, Bonora S, Cingolani A, Di Biagio A, Gianotti N, Guaraldi G, Lo Caputo S, Madeddu G, Maggi P, Marchetti G, Nozza S, Rusconi S, Maggiolo F. Taramasso L, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):610-623. doi: 10.1093/jac/dkaf025. J Antimicrob Chemother. 2025. PMID: 39888371 Review.